Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -6.12% and Operating profit at -37.85% over the last 5 years
- OPERATING CASH FLOW(Y) Highest at CNY 1,067.07 MM
- PRE-TAX PROFIT(Q) At CNY 260.53 MM has Grown at 2,694.24%
- NET PROFIT(Q) At CNY 232.97 MM has Grown at 676.7%
2
Risky -
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 18,670 Million (Large Cap)
NA (Loss Making)
NA
2.31%
0.20
-1.32%
1.77
Revenue and Profits:
Net Sales:
2,579 Million
(Quarterly Results - Mar 2026)
Net Profit:
303 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.48%
0%
-7.48%
6 Months
-7.43%
0%
-7.43%
1 Year
1.64%
0%
1.64%
2 Years
-4.63%
0%
-4.63%
3 Years
-25.9%
0%
-25.9%
4 Years
-11.7%
0%
-11.7%
5 Years
-25.9%
0%
-25.9%
Shandong Buchang Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-6.12%
EBIT Growth (5y)
-37.85%
EBIT to Interest (avg)
9.21
Debt to EBITDA (avg)
1.59
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.81
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.76%
ROE (avg)
7.29%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.79
EV to EBIT
173.76
EV to EBITDA
29.44
EV to Capital Employed
1.69
EV to Sales
1.89
PEG Ratio
NA
Dividend Yield
2.24%
ROCE (Latest)
0.97%
ROE (Latest)
-2.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,579.00
3,406.40
-24.29%
Operating Profit (PBDIT) excl Other Income
419.80
146.00
187.53%
Interest
28.70
30.10
-4.65%
Exceptional Items
-2.40
-512.50
99.53%
Consolidate Net Profit
303.10
-598.80
150.62%
Operating Profit Margin (Excl OI)
162.80%
14.10%
14.87%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -24.29% vs 21.45% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 150.62% vs -398.06% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
11,762.50
10,916.70
7.75%
Operating Profit (PBDIT) excl Other Income
1,191.30
1,297.20
-8.16%
Interest
126.30
135.70
-6.93%
Exceptional Items
-596.20
-898.60
33.65%
Consolidate Net Profit
192.30
-702.40
127.38%
Operating Profit Margin (Excl OI)
101.30%
62.70%
3.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.75% vs -16.72% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 127.38% vs -562.41% in Dec 2024
About Shandong Buchang Pharmaceuticals Co., Ltd. 
Shandong Buchang Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






